RAPT Therapeutics

News

GSK reaches $2.2bn deal to buy food allergy biotech RAPT

GSK has made its first major acquisition under new CEO Luke Miels, buying RAPT Therapeutics and its food allergy prevention drug ozureprubart.

News

RAPT hit by FDA clinical hold on eczema, asthma drug

RAPT Therapeutics has seen its shares fall sharply after the FDA placed a clinical hold on oral CCR4 antagonist zelnecirnon, currently in a phase 2b trial for atopic derma

Oncology

pharmaphorum podcast Episode 241, Mohit Manrao, AstraZeneca

On AI and equity in the cancer setting, with Mohit Manrao

Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at AstraZeneca, and president of the AstraZeneca Foundation.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks